Lataa...
Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites
Nazartinib (EGF816, NZB) is a promising third-generation human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This novel irreversible mutant-selective EGFR inhibitor targets EGFR containing both the resistance mutation (T790M) and the activating mutations (L858R and Del19), while...
Tallennettuna:
| Julkaisussa: | R Soc Open Sci |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
The Royal Society
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6731747/ https://ncbi.nlm.nih.gov/pubmed/31598253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1098/rsos.190852 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|